According to a post yesterday (here), the Association for Accessible Medicines (AAM) Board of Directors has announced the appointment of John A. Murphy, III as the association’s President and Chief Executive Officer. Mr. Murphy will join AAM in October from the Biotechnology Innovation Organization (BIO) where he served as Chief Policy Officer.
Mr. Murphy is a lawyer and, prior to his position at BIO, he served as Assistant General Counsel at Pharmaceutical Research and Manufacturers of America (PhRMA). In addition, he practiced law at the firm Hogan Lovells, LLP, also in the healthcare arena.
His appointment comes at a critical time as PBMs, insurers, pricing pressures, and other concerns, including patent and legal issues, threaten the future of the generic and biosimilar industry.
We welcome Mr. Murphy and his talents to the AAM and wish him the best of luck and success in his new position. All of us in the generic and biosimilar industry look forward to working with him. Also, I feel I would be remiss in not mentioning the great job that interim President and CEO David Gaugh has done for the past two years at AAM as he now passes the baton to his successor.
